Aggressive chemotherapy combined with G-CSF and maintenance therapy with interleukin-2 for patients with advanced myelodysplastic syndrome, subacute or secondary acute myeloid leukemia — initial results

1993 ◽  
Vol 66 (3) ◽  
pp. 123-125 ◽  
Author(s):  
A. Ganser ◽  
G. Heil ◽  
K. Kolbe ◽  
G. Maschmeyer ◽  
J. T. Fischer ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Maintenance Therapy ◽  
Myelodysplastic Syndrome ◽  
Myeloid Leukemia ◽  
Interleukin 2 ◽  
Secondary Acute Myeloid Leukemia ◽  
Initial Results ◽  
Acute Myeloid

scholarly journals A Case of Secondary Leukemia Subsequent to Myelodysplastic Syndromes Successfully Treated with Azacitidine

2014 ◽  
Vol 2014 ◽  
pp. 1-3 ◽  
Author(s):  
Takahiro Kumode ◽  
Ayano Fukui ◽  
Go Eguchi ◽  
Terufumi Yamaguchi ◽  
Yasuhiro Maeda
Keyword(s):  
Acute Myeloid Leukemia ◽  
Elderly Patients ◽  
Myelodysplastic Syndrome ◽  
Physical Condition ◽  
Myeloid Leukemia ◽  
Therapeutic Option ◽  
Tumor Burden ◽  
Secondary Leukemia ◽  
Secondary Acute Myeloid Leukemia ◽  
Acute Myeloid

Elderly patients with secondary acute myeloid leukemia (AML) following myelodysplastic syndrome (MDS) are often medically unfit for or resistant to chemotherapy, and their prognosis is dismal. In the present paper, we reported a case of secondary leukemia following MDS in an 80-year-old male patient who was deemed unfit for chemotherapy owing to his old age and poor physical condition. Despite a high tumor burden, treatment with AZA exerted a remarkable response, leading to an immediate cytoreduction in our case. Our results suggest that AZA can be an attractive therapeutic option for elderly MDS or AML patients, offering adequate efficacy and high tolerability.

Randomized Study of Intensified Anthracycline Doses for Induction and Recombinant Interleukin-2 for Maintenance in Patients With Acute Myeloid Leukemia Age 50 to 70 Years: Results of the ALFA-9801 Study

2010 ◽  
Vol 28 (5) ◽  
pp. 808-814 ◽  
Author(s):  
Cecile Pautas ◽  
Fatiha Merabet ◽  
Xavier Thomas ◽  
Emmanuel Raffoux ◽  
Claude Gardin ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Maintenance Therapy ◽  
Myeloid Leukemia ◽  
Remission Rate ◽  
Interleukin 2 ◽  
Total Duration ◽  
Remission Induction ◽  
Recombinant Interleukin 2 ◽  
High Doses ◽  
Acute Myeloid

PurposeIn patients with acute myeloid leukemia (AML), induction chemotherapy is based on standard doses of anthracyclines and cytarabine. High doses of cytarabine have been reported as being too toxic for patients older than age 50 years, but few studies have evaluated intensified doses of anthracyclines.Patients and MethodsIn this randomized Acute Leukemia French Association 9801 (ALFA-9801) study, high doses of daunorubicin (DNR; 80 mg/m2/d × 3 days) or idarubicin (IDA4; 12 mg/m2/d × 4 days) were compared with standard doses of idarubicin (IDA3; 12 mg/m2/d × 3 days) for remission induction in patients age 50 to 70 years, with an event-free survival (EFS) end point. After two consolidation courses based on intermediate doses of cytarabine, patients in continuous remission were randomly assigned to receive or not receive maintenance therapy with recombinant interleukin-2 (rIL-2; 5 × 106U/m2× 5 days each month) for a total duration of 12 months. A total of 468 patients entered the study (median age, 60 years).ResultsOverall complete remission rate was 77% with significant differences among the three randomization arms (83%, 78%, and 70% in the IDA3, IDA4, and DNR arms, respectively; P = .04). However, no significant differences were observed in relapse incidence, EFS, or overall survival among the three arms. In the 161 patients randomly assigned for maintenance therapy, no difference in outcome was observed between the rIL-2 and the no further treatment arms.ConclusionNeither intensification of anthracycline doses nor maintenance with rIL-2 showed a significant impact on AML course, at least as scheduled in this trial.

Sign in / Sign up

Export Citation Format

Share Document